<DOC>
	<DOCNO>NCT02303626</DOCNO>
	<brief_summary>This study evaluate safety efficacy oral treatment , BCX4161 , prevent acute attack subject hereditary angioedema ( HAE ) . Eligible subject randomize receive one two dos BCX4161 placebo 12 week . The study compare number acute attack treatment group , well number clinical outcome , safety tolerability dose BCX4161 compare placebo .</brief_summary>
	<brief_title>12-Week Safety Efficacy Study BCX4161 Oral Prophylaxis Against HAE Attacks</brief_title>
	<detailed_description />
	<mesh_term>Angioedema</mesh_term>
	<mesh_term>Angioedemas , Hereditary</mesh_term>
	<criteria>Key 1 . A clinical diagnosis HAE type I II 2 . Documented HAE attack within define calendar period ; absence document HAE attack , subject require enter runin period document attack 3 . Access acute attack medication 4 . Sexually active woman childbearing potential sexually active men must utilize highly effective contraception Key 1 . Women pregnant breastfeed 2 . Any clinical condition medical history would interfere subject 's safety ability participate study 3 . Use C1INH tranexamic acid prophylaxis HAE attack 4 . Current participation investigational drug study within last 30 day 5 . History current alcohol drug abuse 6 . Infection hepatitis B , hepatitis C HIV</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2016</verification_date>
	<keyword>BCX4161</keyword>
	<keyword>Prophylaxis</keyword>
	<keyword>Prevention</keyword>
	<keyword>HAE</keyword>
	<keyword>Hereditary Angioedema</keyword>
</DOC>